David Amsellem

Why This Teva Pharmaceutical Analyst Is Turning Bullish On The Austedo Franchise

Akorn Upgraded By Piper Jaffray On Improved Cost Structure, Product Potential

Piper Jaffray Loses Confidence In Insys Therapeutics, Downgrades Stock

Akorn Upgraded By Piper Jaffray On Improved Cost Structure, Product Potential

Piper Jaffray Loses Confidence In Insys Therapeutics, Downgrades Stock

Piper Jaffray Upgrades Supernus Pharmaceutical On Possible Label Expansion For Seizure Drug

Piper Jaffray Staying Bullish On Mallinckrodt

Piper Jaffray Upgrades Supernus Pharmaceutical On Possible Label Expansion For Seizure Drug

Piper Jaffray Staying Bullish On Mallinckrodt

Piper Jaffray On FDA Approval Of Insys Therapeutics' Anorexia Drug Syndros

Jazz Pharma On Track To Report Top-Line, Late-Stage Results Of JZP-110 By December

David Amsellem Recent News

Piper Jaffray Analyst: Latest Report On Valeant 'Doesn't Surprise Me'

Piper Jaffray Downgrades Allergan, Slashes Target To $238

Amsellem: Valeant Has No Floor

Valeant's Calls To Analysts 'Raise Disclosure Questions'

UPDATE: Piper Jaffray Upgrades Forest Laboratories, Previous Thesis is No Longer Tenable

UPDATE: Piper Jaffray Initiates Coverage on Discovery Laboratories on Emerging Respiratory Franchise at Breathtaking Value

UPDATE: Piper Jaffray Downgrades Santarus Following Salix Acquisition Announcement

UPDATE: Piper Jaffray Upgrades Endo Health Solutions as Paladin Transaction is a Game-Changer

UPDATE: Piper Jaffray Downgrades Pacira Pharmaceuticals Following 2Q13 Net Loss

UPDATE: Piper Jaffray Upgrades Questcor Pharmaceuticals Following Strong 2Q13 Report

UPDATE: Piper Jaffray Lowers PT on Allergan Following FDA Draft Guidance

UPDATE: Piper Jaffray Initiates Cadence Pharmaceuticals at Neutral, Generics Likely to Continue Gaining Traction

UPDATE: Piper Jaffray Initiates The Medicines Company at Overweight on Diverse Medical Portfolio

UPDATE: Piper Jaffray Raises PT on Actavis on Pro Forma Estimates

Salix Pharmaceuticals (SLXP) Gets Overweight From Piper Jaffray

Impax Weakness Overblown, Cash Still Flowing; Piper Jaffray (IPXL)

Piper Jaffray Reiterates Salix Pharmaceuticals (SLXP) Overweight Rating